An observational study in Alzheimer s Disease and Mild Cognitive Impairment (MCI), sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Chinese University of Hong Kong · Observational
Population aging is transforming the epidemiological landscape of the Asia-Pacific region at an unprecedented pace. By 2050, more than one quarter of the region's population will be aged over 60, with 36.7% of countries projected to become" super-aged" societies.
Within Hong Kong specifically, the age- and gender-adjusted prevalence rates of mild and major neurocognitive disorder (NCD) among adults aged 60 years or above have been estimated at 21.8% and 9.7%, respectively. The scale of this burden intensifies considerably within institutional care environments, where roughly seven in ten long-term care (LTC) residents have been identified as having major NCD. Recent local survey data also indicate that severe cognitive impairment affects up to 49.8% of residents aged above 85 years. Given current demographic trajectories, the number of individuals living with dementia in Hong Kong is projected to triple over the next two decades. These trends underscore an urgent, time-sensitive need for scalable, accurate, and population-appropriate tools for the early detection and prognostic stratification of cognitive impairment, tools that must be actionable at the point of care and deployable at population scale.
This study aim to generate a large database of cognitive, neuroimaging, plasma biomarkers, lifestyle and psychological information of the subjects who suffered from neurocognitive disorders
3,941 studies on the registry are indexed under Cognitive Dysfunction; 1,117 are open to participants now.
This study's planned enrollment of 1,600 is above the median of 150 across 995 observational studies indexed under Cognitive Dysfunction.
Browse Cognitive Dysfunction studies →Chinese University of Hong Kong is the lead sponsor of 1,453 studies on the registry; 474 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects will be identified from community, existing cohorts and specialist clinics
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject with mild cognitive impairment, which identified with CDR =0.5
Subject with mild cognitive impairment, which identified with CDR =1
Hong Kong Montreal Cognitive Assessment (HK-MoCA)
The HK-MoCA is a locally validated, brief cognitive screening tool assessing multiple domains including attention, executive function, memory, language, visuospatial ability, and orientation, and is widely used to detect mild cognitive impairment in the Hong Kong Chinese population. The total score is 30. The lower the score, the higher risk of cognitive impairment
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
Clinical Dementia Rating
The CDR is a semi-structured interview-based staging instrument that evaluates both cognitive and functional performance across six domains (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care), yielding a global score that reflects overall severity of cognitive impairment (0 = normal, 0.5 = questionable/very mild, 1 = mild, 2 = moderate, 3 = severe).
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
Hong Kong List Learning Test
The HKLLT is a culturally adapted verbal list-learning test modeled after the California Verbal Learning Test, used to assess verbal learning and memory, with Trial 4 (T4, delayed recall) serving as a sensitive index of episodic memory decline. The lower the standard deviation of the Trial 4 recall, the higher the risk of cognitive impairment
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
Simple Mild Neurocognitive Disorder due to Alzheimer's Disease Risk Test (SMART)
The SMART is a novel digitalised tool that incorporates both subjective and objective measures of cognitive impairment. it incorporates immediate recall, delayed recall, and verbal fluency tasks. The lower the z-score, the higher the risk of cognitive impairment
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
The pathological findings and changes on PET imaging
An amyloid PET (Positron Emission Tomography) scan measures beta-amyloid plaques in the brain which lead to Alzheimer's disease (AD) pathogenesis. The key quantitative measurements are Standarized uptake value ratio (SUVR) and Centiloid Scale (CL) . The higher the vlaue of SUVR and CL reflect greater amyloid accumulation in the brain.
Time frame: baseline and 3 year follow up
The pathological findings and changes on MRI
A MRI brain scan mainly investigate and measure the structure of the brain. Volume of specific brain regions (such as the hippocampus, ventricles, or total gray/white matter) in cubic centimeters (cm³)
Time frame: baseline and 3 year follow up
Blood biomarkers
Biomarkers will include molecular and cellular assays, genomic, epigenomic, and other multi-omic assays for both cellular and acellular fractions.
Time frame: Baseline, 1 year, 2 years, 3 years, 4 years, 5 years and 6 years follow up
Other open studies at The Chinese University of Hong Kong, Hong Kong
Open a list, then choose Watch this search to get new studies there in a weekly email.
Plan to share: Undecided
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →